Abstract:BackgroundWe developed a novel system for quantifying DNA damage response (DDR) to help diagnose and predict the risk of Alzheimer's disease (AD). MethodsWe thoroughly estimated the DDR patterns in AD patients Using 179 DDR regulators. Single-cell techniques were conducted to validate the DDR levels and intercellular communications in cognitively impaired patients. The consensus clustering algorithm was utilized to group 167 AD patients into diverse subgroups after a WGCNA approach was employed to discover DDR-related lncRNAs. The distinctions between the categories in terms of clinical characteristics, DDR levels, biological behaviors, and immunological characteristics were evaluated. For the purpose of choosing distinctive lncRNAs associated with DDR, four machine learning algorithms, including LASSO, SVM-RFE, RF, and XGBoost, were utilized. A risk model was established based on the characteristic lncRNAs. ResultsThe progression of AD was highly correlated with DDR levels. Single-cell studies confirmed that DDR activity was lower in cognitively impaired patients and was mainly enriched in T cells and B cells. DDR-related lncRNAs were discovered based on gene expression, and two different heterogeneous subtypes (C1 and C2) were identified. DDR C1 belonged to the non-immune phenotype, while DDR C2 was regarded as the immune phenotype. Based on various machine learning techniques, four distinctive lncRNAs associated with DDR, including FBXO30-DT, TBX2-AS1, ADAMTS9-AS2, and MEG3 were discovered. The 4-lncRNA based riskScore demonstrated acceptable efficacy in the diagnosis of AD and offered significant clinical advantages to AD patients. The riskScore ultimately divided AD patients into low- and high-risk categories. In comparison to the low-risk group, high-risk patients showed lower DDR activity, accompanied by higher levels of immune infiltration and immunological score. The prospective medications for the treatment of AD patients with low and high risk also included arachidonyltrifluoromethane and TTNPB, respectively, ConclusionsIn conclusion, immunological microenvironment and disease progression in AD patients were significantly predicted by DDR-associated genes and lncRNAs. A theoretical underpinning for the individualized treatment of AD patients was provided by the suggested genetic subtypes and risk model based on DDR.

Integrative analysis of single-nucleus RNA sequencing and Mendelian randomization to explore novel risk genes for Alzheimer's disease

Integration of single-cell sequencing with machine learning and Mendelian randomization analysis identifies the NAP1L1 gene as a predictive biomarker for Alzheimer's disease

Mendelian randomization to evaluate the effect of folic acid supplement on the risk of Alzheimer disease

Single Nucleotide Polymorphism and Alzheimer¢s Disease

Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk

Systematic evaluation of multifactorial causal associations for Alzheimer's disease and an interactive platform based on Mendelian randomization analysis----MRAD

Integration of Bulk RNA Sequencing and Single-Cell Analysis Reveals a Global Landscape of DNA Damage Response in the Immune Environment of Alzheimer's Disease

Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer’s disease

Systematic evaluation of multifactorial causal associations for Alzheimer's disease and an interactive platform based on Mendelian randomization analysis——MRAD

Identification of novel risk genes for Alzheimer's disease by integrating genetics from hippocampus

Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis

Systematic evaluation of multifactorial causal associations for Alzheimer's disease and an interactive platform MRAD developed based on Mendelian randomization analysis

Senescence-related genes and proteins in the development of Alzheimer's disease: evidence from transcriptomic and Mendelian randomization analysis

Single cell transcriptomes and multiscale networks from persons with and without Alzheimer's disease

Exploring Potential Biomarkers Underlying the Pathogenesis of Alzheimer's Disease by Bioinformatics Gene Analysis.

Whole Exome Sequencing Analyses Identified Novel Genes for Alzheimer's Disease and Related Dementia

Identification of Alzheimer's Disease-Related Genes Based on Data Integration Method

Elucidating the Functional Roles of Long Non-Coding RNAs in Alzheimer's Disease

Identifying Alzheimer's disease-related pathways based on whole-genome sequencing data

Integrated Identification of Key Genes and Pathways in Alzheimer’s Disease Via Comprehensive Bioinformatical Analyses

Molecular Subtyping of Alzheimer's Disease Using RNA Sequencing Data Reveals Novel Mechanisms and Targets.